<DOC>
	<DOCNO>NCT02507804</DOCNO>
	<brief_summary>The aim study design evaluate PROMs diary cancer patient self report side effect experience treatment , thereby create detailed account treatment related adverse event impact daily activity share care team .</brief_summary>
	<brief_title>A Study Evaluate Diary Patient Reported Outcome Measures ( PROMs )</brief_title>
	<detailed_description>This randomise , control , single-centred study compare quality Adverse Events ( AE ) Concomitant Medication ( CM ) reporting , patient satisfaction , care experience quality life cancer patient undergo chemotherapy manage with/without diary Patient Reported Outcome Measures . 164 subject enrol randomise 1:1 ratio stratify line therapy ( first line v second line high line ) , treatment intent ( curative v palliative ) ECOG performance status ( 0-1 v 2-3 ) . All subject receive standard chemotherapy deliver per institutional practice . They also receive counsel monitoring report side effect , medication experience per standard practice . All subject complete study questionnaire EQ-5D form Outpatient Department prior consultation delivery chemotherapy . Subjects randomise Arm A use PROMs diary record side effect , medication experience associate cycle 1-6 chemotherapy . The diary reviewed study team collect AE CM information . AE/CM record source document per usual practice . Subjects randomise control Arm B discuss side effect , medication experience associate cycle 1-6 chemotherapy clinical consultation per standard practice . This may include use note , diary method discretion . Arm B subject may use PROMs diary . The study team collect record AE/CM information source documentation per usual practice .</detailed_description>
	<criteria>Adult patient age 18 ; upper age limit . Cancer require commencement chemotherapy ( line ) regime contain least 6 cycle ( cycle duration ) . Chemotherapy may include systematic anticancer therapy ( i.e . cytotoxic agent , immunotherapy target therapy ) provide deliver induction therapy . Expectation complete cycle 1 6 plan therapy . The capacity understand Patient Information Sheet provide write informed consent . Non English speaking patient may enter study English speak friend relative willing assist patient . Willingness ability comply study procedure . A patient enrol concurrent IMP clinical trial permit Investigators discretion . Patients already commence therapy current disease episode i.e . receive least first cycle chemotherapy . Patients receive chemotherapy/ radioimmunotherapy sole modality treatment . Patients complete induction therapy due commence maintenance therapy . Uncontrolled medical condition opinion Investigator may jeopardise completion 6 cycle treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>